ARTICLE | Product Development
FDA dings Regeneron for seeking accelerated approval before launching trials to confirm benefit
By Steve Usdin, Washington Editor
March 26, 2024 12:57 AM UTC
Updated on Mar 26, 2024 at 5:50 PM UTC
Editor’s note: This article has been updated to reflect Regeneron’s compassionate use program for odronextamab
On December 29, 2022, Congress gave FDA the power to refuse to approve an application for accelerated approval if a trial to confirm clinical benefit was not under way. The agency has used that power for the first time, issuing complete response letters to Regeneron for odronextamab, a CD20xCD3 bispecific, for treatment of relapsed or refractory follicular lymphoma and relapsed or refractory diffuse large B cell lymphoma.
Announcing the CRLs Monday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stated that the “only approvability issue is related to the enrollment status of the confirmatory trials,” and that FDA “did not identify any approvability issues with the odronextamab clinical efficacy or safety, trial design, labeling or manufacturing.”…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651899/first-complete-response-letter-for-lack-of-confirmatory-trial-enrollment